The 16-membered macrolide FD-891 exerts cytotoxicity toward several cancer cell lines. In this study, we showed that FD-891 induces apoptosis in various human cancer cell lines. Human leukemia Jurkat cells were highly sensitive to FD-891, exhibiting caspase activation and mitochondrial release of cytochrome c into the cytosol at early time points after exposure to FD-891. By contrast, Jurkat cells deficient in caspase-8 were resistant to FD-891-induced apoptosis and manifested little induction of cytochrome c release as well as caspase-9 processing. Consistent with these results, the overexpression of the Bcl-2 family member Bcl-x L or the caspase-8 modulator c-FLIP L markedly prevented FD-891-induced apoptosis. These results clearly demonstrate that FD-891 triggers caspase-8-dependent mitochondrial release of cytochrome c and subsequent apoptosis in Jurkat cells.
INTRODUCTION
Apoptosis is a physiological process that has an important role in the homeostasis of mature tissues. Caspases are a family of cysteine proteinases that are essential for apoptosis and act by cleaving selected substrates. [1] [2] [3] Initiator caspase-8 is converted into active forms via dimerization and self-processing, and subsequently cleaves various substrates, such as effector caspases and BH3-only protein Bid, to produce their active forms. [1] [2] [3] Truncated Bid is translocated to mitochondria where it initiates the release of pro-apoptotic proteins into the cytosol. 4, 5 Mitochondrial pro-apoptotic proteins, such as cytochrome c, are confined to intermembrane space and liberated into the cytosol in response to apoptotic stimuli. 6, 7 Cytochrome c collaborates with adaptor protein Apaf-1 to activate initiator caspase-9. [8] [9] [10] Effector caspases-3, -6, and -7 are processed into their active forms by activated caspase-9 and the activated caspases mediate the proteolytic cleavage of cellular proteins required for apoptosis. 11 The cytotoxic macrolide FD-891 was originally isolated from the fermentation broth of Streptomyces graminofaciens A-8890. 12, 13 The absolute structure of FD-891 was determined in our earlier work ( Figure 1a) 14, 15 and its planar structure turned out to be the same as that of BE-45653. 16 The total synthesis of FD-891 was recently reported. [17] [18] [19] It has been shown that FD-891 exerts cytotoxicity toward several cancer cell lines. 12, 19 Moreover, as regards immunosuppressive activity, FD-891 prevents cytotoxic T lymphocyte (CTL) mediated killing pathway. 20 In this study, we investigated the molecular mechanism underlying the cytotoxicity of FD-891. Our present results demonstrate that FD-891 triggers caspase-8-dependent mitochondrial release of cytochrome c and subsequent apoptosis in a human leukemia cell line highly sensitive to FD-891.
MATERIALS AND METHODS Cells
Human lung carcinoma A549 cells, human fibrosarcoma HT-1080 cells and human rhabdomyosarcoma Kym-1 cells were obtained from the Health Science Research Resources Bank (Osaka, Japan). Caspase-8-deficient Jurkat cell clone (I9.2), 21 c-FLIP L -transfected Jurkat cell clone (JFL2), 22 and Bcl-x L -transfected Jurkat cell clone (Jurkat-Bcl-x L #1) 23 were described previously. Human cancer cell lines were maintained in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% (v/v) heat-inactivated fetal calf serum (JRH Bioscience, Lenexa, KS, USA), penicillin G (100 U ml -1 ) (Sigma-Aldrich, St Louis, MO, USA) and streptomycin (100 mg ml -1 ) (Sigma-Aldrich).
Reagents FD-891 was purified from the fermentation broth of S. graminofaciens A-8890 as previously described. 12 Doxorubicin, etoposide and vincristine were purchased from Sigma-Aldrich.
Antibodies
Antibodies to caspase-3 (H-277; Santa Cruz Biotechnology, Santa Cruz, CA, USA), caspase-6 (3E8; Medical & Biological Laboratories (MBL), Nagoya, Japan), caspase-7 (11E4; Sigma-Aldrich), caspase-8 (5F7; MBL), caspase-9 (5B4; MBL), cytochrome c (7H8.2C12; BD Biosciences, Franklin Lakes, NJ, USA), and PARP (C-2-10; Sigma-Aldrich) were commercially obtained.
Assay for cell viability
Cells were pulsed with 500 mg ml -1 of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) for 4 h. MTT formazan was solubilized with 10% sodium dodecyl sulfate (SDS) overnight. Absorbance at 595 nm was measured with a Model 680 microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). Cell viability (%) was calculated as [(experimental absorbance-background absorbance)/(control absorbance -background absorbance)]Â100.
Assay for apoptosis
Cells were fixed with PBS containing 4% paraformaldehyde at 4 1C overnight, and then stained with 300 mM Hoechst 33342 (Calbiochem, San Diego, CA, USA). Nuclear morphology was observed under a fluorescence light microscope (Axiovert 200 M; Carl Zeiss, Jena, Germany). Apoptotic cells (%) were calculated as (condensed nuclei/total nuclei)Â100.
Preparation of cell lysates
Cells were washed with PBS and lysed in Triton X-100 lysis buffer consisting of 50 mM Tris-HCl (pH 7.4), 1% Triton X-100, 2 mM DTT, 2 mM sodium orthovanadate, and the protease inhibitor mixture Complete (Roche Diagnostics, 
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Mannheim, Germany). Postnuclear lysates were collected as supernatants by centrifugation (10 000 g, 5 min). Alternatively, cells were washed with PBS and lysed with digitonin lysis buffer (10 mM Hepes-KOH (pH 7.2), 100 mM digitonin, 250 mM sucrose, 1 mM DTT, 5 mM EGTA, 2 mM MgCl 2 , 50 mM NaCl and the protease inhibitor mixture Complete) on ice for 15 min. After centrifugation (10 000 g, 5 min), cell lysates containing the cytosol were recovered as supernatants. Pellets were washed once with digitonin lysis buffer and treated with Triton X-100 lysis buffer on ice for 15 min. After centrifugation (10 000 g, 5 min), cell lysates containing the mitochondria were collected as supernatants (mitochondrial fraction).
Western blotting
Protein samples (30 mg per lane) were separated by SDS-PAGE and transferred onto Hybond-ECL nitrocellulose membranes (GE Healthcare, Piscataway, NJ, USA). The transferred membranes were stained with Ponceau S and checked for equal loading of proteins before antibody reaction. The membranes were incubated with primary antibodies and then with horseradish peroxidaseconjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA), followed by analysis using ECL western blotting detection reagents (GE Healthcare).
RESULTS

FD-891 inhibits proliferation of human cancer cell lines
It has been shown that FD-891 exerts cytotoxicity toward several cancer cell lines. 12, 19 (Table 1) . In Jurkat cells, FD-891 decreased cell viability by more than 80% at concentrations higher than 100 nM when incubated for 72 h (Figure 1b) . Kinetic studies revealed that FD-891 gradually reduced cell viability during incubation for 24 to 72 h (Figure 1c ).
FD-891 induces apoptosis of human cancer cell lines
To investigate whether FD-891 is able to induce apoptosis, Jurkat cells were incubated with various concentrations of FD-891 for 24 h and nuclear morphological changes were analyzed by fluorescence microscopy after Hoechst 33342 staining. FD-891 at concentrations higher than 100 nM was found to induce nuclear condensation and fragmentation characteristic of apoptosis within 24 h (Figure 2a ). Kinetic studies revealed that FD-891 initiated apoptosis within 6 h and that the number of apoptotic cells steadily increased during 24 h incubation ( Figure 2b ). Various human cancer cell lines were also found to undergo apoptosis upon treatment with FD-891. FD-891 was able to induce apoptosis very strongly in two leukemia cell lines (that is, Jurkat and HL-60), whereas it induced moderate-to-weak apoptosis in 
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the other cancer cell lines (Figure 2c) . Therefore, the results suggest that the induction of apoptosis is correlated with the inhibitory effect of FD-891 on cell proliferation at least in Jurkat and HL-60 cells. However, non-apoptotic cells harboring two nuclei apparently accumulated in FD-891-treated cells (unpublished observation). Therefore, as previously reported, 19 it seems that FD-891 induces cell cycle arrest at the G 2 /M phase, and this biological effect may also contribute to its inhibitory effect on cell proliferation. In this study, the molecular mechanism underlying FD-891-induced apoptosis in Jurkat cells was further addressed.
FD-891 induces activation of caspases
Poly(ADP-ribose)polymerase (PARP) is a nuclear protein that is processed by effector caspases during apoptosis. 24 When Jurkat cells were incubated with FD-891, full-length PARP (116 kDa) was processed into the cleaved form (85 kDa) during 6 to 24 h incubation (Figure 3a) . Likewise, caspase-3, caspase-6 and caspase-7 were processed into their active forms in FD-891-treated cells with similar kinetics (Figure 3b ). Initiator caspase-9 was also processed into p35 and p37 fragments at earlier time points than other effector caspases when Jurkat cells were exposed to FD-891 ( Figure 3c ). We previously reported that chemotherapeutic agents, such as doxorubicin, etoposide and vincristine, induce apoptosis in Jurkat cells. 25 Similar to FD-891, doxorubicin, etoposide and vincristine were able to induce the processing of caspase-3, caspase-6 and caspase-7 into their active forms (Figure 3e) . However, at the concentrations that reduced cell viability to approximately 50% within 24 h, these chemotherapeutic drugs were able to induce the activation of effector caspases more effectively than FD-891 (Figures 3d and e) . Thus, the results suggest that FD-891 may induce caspase activation in a manner distinct from doxorubicin, etoposide and vincristine.
FD-891 induces mitochondrial release of cytochrome c
Mitochondria has an essential role in the induction of apoptosis by releasing pro-apoptotic proteins, such as cytochrome c, into the cytosol. 6, 7 Upon treatment with FD-891, cytochrome c was released from the mitochondria into the cytosol in Jurkat cells (Figure 4a ). The Bcl-2 family of proteins regulates cytochrome c release and subsequent induction of apoptosis. 6, 7 The overexpression of Bcl-x L markedly inhibited apoptosis induced by FD-891 (Figure 4b ). These results suggest that the mitochondrial release of cytochrome c is required for FD-891-induced apoptosis.
Caspase-8 is required for mitochondrial release of cytochrome c during FD-891-induced apoptosis Caspase-8 is an initiator caspase that undergoes self-processing into its active forms in response to various stimuli. [1] [2] [3] In Jurkat cells, caspase-8 was processed into p43/p41 fragments during FD-891-induced apoptosis (Figure 5a ). However, in contrast to Fas ligand (FasL) stimulation, p18 large fragments were barely detectable in FD-891-treated cells (Figure 5a ). To address if caspase-8 is required for FD-891-induced apoptosis, Jurkat cells deficient in caspase-8 were compared with wild-type cells for the induction of apoptosis upon exposure to FD-891. Caspase-8-deficient cells manifested resistance to FD-891-induced apoptosis (Figure 5b ). The overexpression of the caspase-8 modulator c-FLIP L also conferred resistance to FD-891-induced apoptosis in Jurkat cells (Figure 5c ), supporting the notion that caspase-8 is required for FD-891-induced apoptosis. In caspase-8-deficient cells, FD-891 barely induced the release of cytochrome c into the cytosol (Figure 5d ). Consistently, caspase-9 processing was also inhibited in caspase-8-deficient cells treated with FD-891 (Figure 5e ).
Together, the results demonstrate that caspase-8 is required for the release of cytochrome c to the cytosol and the subsequent activation of caspase-9. It has been shown that FD-891 inhibits cell proliferation in cancer cell lines. 12, 19 Consistent with these findings, we have shown that FD-891 is able to inhibit cell proliferation in many human cancer cell lines at IC 50 values of 0.03 to 1 mM. Human leukemia cell lines, such as Jurkat cells and HeLa cells, were highly sensitive to FD-891 and underwent rapid apoptosis upon treatment with FD-891. However, in some cancer cell lines, FD-891 barely induced apoptosis even at 10 mM, suggesting that the FD-891-induced apoptosis is cell typespecific. It has been shown that FD-891 induces accumulation of cancer cells at the G 2 /M phase during the cell cycle. 19 Therefore, it seems likely that FD-891 predominantly induces cell cycle arrest, thereby inhibiting cell proliferation in cancer cell lines refractory to apoptosis.
Chemotherapeutic drugs, such as doxorubicin, etoposide and vincristine, are known to induce caspase-dependent apoptosis in various types of cancer cells. We previously showed that the over- 25 indicating that caspase-8 is dispensable for apoptosis induced by these chemotherapeutic drugs. However, it seems that caspase-8 activation is required for FD-891-induced apoptosis, as c-FLIP L overexpression or caspase-8 deficiency markedly prevented FD-891-induced apoptosis. Therefore, as the main apoptosis-signaling pathway, FD-891 is likely to induce the mitochondrial release of cytochrome c as well as caspase-9 processing through caspase-8 activation.
In addition to the cytotoxicity toward cancer cells, we have previously shown that FD-891 prevents the interaction between CTLs and target cells, thereby inhibiting CTL-mediated killing pathways. 20 Structurally related 16-and 18-membered macrolides (bafilomycin A 1 and concanamycin A, respectively), known as inhibitors of vacuolar-type H + -ATPase, manifested inhibitory profiles different from FD-891 in the CTL-mediated killing pathway, 26 in agreement with the fact that FD-891 does not affect vacuolar acidification. 20 The mechanism of action of FD-891 is also distinct from that of known chemotherapeutic drugs (doxorubicin, etoposide and vincristine). To understand anti-cancer and immunosuppressive activities at the molecular level, the molecular target(s) of FD-891 should be identified.
